5th Nov 2008 07:00
5 November 2008
SYNERGY HEALTH PLC
("Synergy", the "Company" or the "Group")
INFECTION PREVENTION PRODUCTS RECOMMENDED BY NHS
Synergy Health plc (LSE: SYR), a leading provider of outsourced healthcare support services in the UK, Continental Europe, Asia and South Africa, announces that two of the Company's ranges of infection control products have been included in the NHS Supply Chain Catalogue and will be made available to all NHS organisations.
Synergy has integrated Byotrol™, a unique infection control technology, into its Azo™ and Oasis™ product ranges which include anti-microbial and patient cleansing devices. Byotrol™ is a unique long-acting biocide which demonstrates broad-based efficacy across all microbial classes, bacteria, viruses, fungi, moulds mycobacteria and algae. The technology is highly effective in the elimination of MRSA (Methicillin-resistant Staphylococcus aureus), C. Difficile and VRE (vancomycin-resistant enterococcus).
Synergy is currently piloting the Byotrol™ technology used in its Azo™ range of products in collaboration with the NHS at a leading UK teaching hospital. Preliminary results from the study showed that Byotrol™ offers a potential performance advantage over traditional chlorine based products whilst minimising damage to equipment. Byotrol™ has also been shown to demonstrate residual efficacy, reducing toxicity issues and overcoming the limitations of other infection control offerings.
According to Richard Deed of TrusTECH, the North West NHS Innovation Hub which is supervising the study, "The interim results are encouraging when compared to chlorine based cleaning. One of the biggest challenges facing the NHS at the moment is to find a technology that offers the biocidal performance of chlorine based products without the damage to equipment & fabric associated with using such products. If the results from this study continue to follow the trends shown to date, the Azo™ range of products could well be the answer to this challenge."
Mike Fazal, Managing Director Healthcare Solutions, said: "Synergy offers a range of products and services to enable hospitals and healthcare operators to improve environmental quality standards and reduce the risk of outbreaks of infections such as MRSA, C. Difficile and VRE. Our Byotrol™ based range of products is an important element of our infection control service offering and we are pleased to have secured a place in the NHS Supply Chain Catalogue with this technology."
- Ends -
Enquiries:
|
Synergy Health plc |
|
|
Mike Fazal, MD Healthcare Solutions |
01793 891851 |
|
Financial Dynamics David Yates / Ben Brewerton Emma Thompson |
020 7831 3113 |
About Synergy Health
Synergy Health (LSE: SYR) is a leading international provider of sterilisation and infection control solutions for hospitals and the healthcare industry. The global market for healthcare continues to expand driven by demographic trends and increased prosperity in developing countries and Synergy is well placed to capitalise on this macro trend. Headquartered in Swindon, United Kingdom, Synergy Health has established a global presence and employs over 3700 people across Europe, Asia, South Africa and the Middle East. The Company is focussed on sustaining its growth through the continued internationalisation of the business, the development of its core services and through the application of its services in new health related markets. For further information please visit www.synergyhealthplc.com
Related Shares:
SYR.L